Stockreport

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

Traws Pharma, Inc.  (TRAW) 
PDF Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end [Read more]